Daily Stock Analysis, CELG, Celgene Corp, priceseries

Celgene Corp. Daily Stock Analysis
Stock Information
Open
109.95
Close
110.02
High
110.53
Low
109.52
Previous Close
110.41
Daily Price Gain
-0.39
YTD High
110.70
YTD High Date
Nov 13, 2019
YTD Low
63.19
YTD Low Date
Jan 2, 2019
YTD Price Change
43.38
YTD Gain
65.10%
52 Week High
110.70
52 Week High Date
Nov 13, 2019
52 Week Low
58.59
52 Week Low Date
Dec 26, 2018
52 Week Price Change
40.04
52 Week Gain
57.22%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 16. 2017
122.36
Jun 30. 2017
129.18
10 Trading Days
5.57%
Link
LONG
Aug 28. 2017
131.65
Sep 27. 2017
143.14
21 Trading Days
8.73%
Link
LONG
Jul 5. 2018
80.39
Aug 15. 2018
89.43
29 Trading Days
11.25%
Link
LONG
Jan 2. 2019
66.64
Feb 4. 2019
87.68
22 Trading Days
31.58%
Link
Company Information
Stock Symbol
CELG
Exchange
NasdaqGS
Company URL
http://www.celgene.com
Company Phone
(908)673-9000
CEO
Mark J. Alles
Headquarters
New Jersey
Business Address
86 MORRIS AVENUE, SUMMIT, NJ 07901
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000816284
About

Celgene Corp. is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Description

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc.; The company was founded in 1980 and is headquartered in Summit, New Jersey.